ENETS guidelines for the management of pancreatic neuroendocrine neoplasms

Medical advisors

This course has been developed in close cooperation with:
Prof. Robert Jensen, Prof. Reza Kianmanesh, Prof. Massimo Falconni and Prof. Dermot O'Toole
ENETS CME course editor: Dr. Christos Toumanakis MD PhD

Target audience

The target audience for this course comprises clinicians in the field of oncology, radiology, surgery, endocrinology, gastroenterology, and pathology. The target audience is expected to have a background knowledge of NEN biology, epidemiology, WHO classification, and survival and prognostic factors.

Length of webinar

60 minutes

Date of webinar

Begin: 28.01.2019
End: 27.01.2021


1 European CME credit (ECMEC)


Prof. Robert Jensen, Prof. Reza Kianmanesh, Prof. Massimo Falconni and Prof. Dermot O'Toole, who are responsible for the medical content, received editorial and writing support in the preparation of this course. The medical advisors are fully responsible for the content and editoral decisions for this course.

Agnieszka Rarok, PhD provided scientific advisory support for this course.

Jenny Lloyd, BSc, PhD, and Nynke Koopen, PhD provided writing and editorial support for this course.


An independent review of this course was conducted by Dr Erika Kovačič Palli, Gastroenterološka interna klinika, Japljeva ulica 2, 1000 Ljubljana, Slovenia.

Technical information

This webinar primarily was provided in flash file format. Due to security reasons it has been remastered and converted into HTML5 standard.

Whenever mentioned in the webinar to use the „Clicking function“ which formerly led to a freeze frame picture, please feel free to stop the video or go back and repeat sequences, if you need additional time for listening or reading.

Learning objectives

Upon completion of this course learners should know the guidelines for management of funtioning and non-functioning pancreatic neuroendocrine neoplasms, including

  • Clinical diagnosis
  • Diagnostic procedures
  • Treatment
  • Management of advanced/ metastatic disease
  • Follow-up